Lenalidomid Avansor

Lenalidomide, the active ingredient in Lenalidomid Avansor, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain hematologic malignancies, including multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomid Avansor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Lenalidomid Avansor (lenalidomide) is used in the management of hematologic cancers that involve abnormal plasma or lymphoid cells. - Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory cases. - Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia.

Lenalidomid Avansor may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often accompanied by vomiting. - Rash: skin irritation or redness. - Constipation: difficulty passing stools. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: blood clots such as deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers, particularly skin cancers.

When prescribing Lenalidomid Avansor, clinicians should consider several safety measures and monitoring requirements. - Pregnancy contraindication: drug is classified as Category X and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Renal function: adjust monitoring in patients with impaired kidney function. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Teratogenicity prevention: ensure effective contraception for both male and female patients of reproductive potential. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct light.

Lenalidomid Avansor can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin, direct oral anticoagulants): increase risk of bleeding. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - Vaccines containing live attenuated viruses: risk of infection due to immunomodulation. - NSAIDs and aspirin: may exacerbate thrombocytopenia.